Musculoskeletal Adverse Effects Associated with Inhaled Levofloxacin in a Patient with Cystic Fibrosis: A Case Report
Abstract
Inhaled levofloxacin is widely used in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection and is generally well tolerated. The most commonly reported adverse effects are bronchospasm and dysgeusia, with limited evidence of systemic toxicity. We report a case of a 26-year-old woman with CF who developed recurrent diffuse musculoskeletal pain temporally associated with inhaled levofloxacin therapy. Symptoms occurred exclusively during treatment cycles, resolved upon discontinuation, and have not recurred since cessation. This case highlights a potential association between inhaled levofloxacin and musculoskeletal adverse effects, emphasizing the need for clinician awareness despite the drug's favorable safety profile.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.